Wealthfront Advisers’s VanEck Biotech ETF BBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.32M Buy
7,004
+1,491
+27% +$287K ﹤0.01% 670
2025
Q4
$1.04M Buy
5,513
+122
+2% +$22.6K ﹤0.01% 705
2025
Q3
$893K Sell
5,391
-554
-9% -$90.3K ﹤0.01% 716
2025
Q2
$911K Sell
5,945
-1,307
-18% -$195K ﹤0.01% 696
2025
Q1
$1.14M Buy
7,252
+1,455
+25% +$236K ﹤0.01% 635
2024
Q4
$910K Buy
5,797
+1,261
+28% +$212K ﹤0.01% 681
2024
Q3
$805K Buy
4,536
+50
+1% +$8.87K ﹤0.01% 688
2024
Q2
$755K Buy
4,486
+1,021
+29% +$167K ﹤0.01% 674
2024
Q1
$576K Buy
3,465
+526
+18% +$87.1K ﹤0.01% 713
2023
Q4
$486K Sell
2,939
-2,290
-44% -$352K ﹤0.01% 726
2023
Q3
$814K Buy
5,229
+1,292
+33% +$206K ﹤0.01% 599
2023
Q2
$614K Buy
3,937
+1,549
+65% +$247K ﹤0.01% 646
2023
Q1
$387K Buy
2,388
+14
+0.6% +$2.27K ﹤0.01% 712
2022
Q4
$379K Buy
2,374
+357
+18% +$56.5K ﹤0.01% 680
2022
Q3
$284K Buy
2,017
+176
+10% +$26.6K ﹤0.01% 698
2022
Q2
$268K Sell
1,841
-59
-3% -$8.79K ﹤0.01% 706
2022
Q1
$308K Buy
1,900
+1
+0.1% +$162 ﹤0.01% 704
2021
Q4
$360K Sell
1,899
-340
-15% -$65.6K ﹤0.01% 647
2021
Q3
$452K Buy
+2,239
New +$470K ﹤0.01% 574

Other funds holding BBH

Wealthfront Advisers's BBH Position: Q1 2026 in Review

Wealthfront Advisers increased its VanEck Biotech ETF (BBH) stake by 27% in Q1 2026, buying an estimated $287K and bringing the position to 7,004 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #670.

Wealthfront Advisers first reported a position in BBH in Q3 2021 and has held it in 19 quarters since. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

  • Wealthfront Advisers held 7,004 shares of VanEck Biotech ETF worth $1.32M as of Q1 2026.
  • Wealthfront Advisers bought 1,491 VanEck Biotech ETF shares in Q1 2026, an estimated $287K.
  • VanEck Biotech ETF made up ﹤0.01% of Wealthfront Advisers's portfolio in Q1 2026, its #670 holding.
  • Wealthfront Advisers first reported a position in VanEck Biotech ETF in Q3 2021 and has held it in 19 quarters since.
  • 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Wealthfront Advisers's 13F filing for Q1 2026, filed 5 May 2026.